Clinical Trial Detail

NCT ID NCT02203513
Title A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

triple-receptor negative breast cancer

ovarian cancer

peritoneum cancer

breast cancer

fallopian tube cancer

Therapies

Prexasertib

Age Groups: senior adult

No variant requirements are available.